Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07007936
PHASE2

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

View on ClinicalTrials.gov

Summary

To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate the Efficacy and Safety of Oral SSS17 Capsules in the Treatment of Anemia Following Total Hip or Knee Arthroplasty

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2025-07

Completion Date

2026-04

Last Updated

2025-06-11

Healthy Volunteers

No

Interventions

DRUG

SSS17 Capsule (6 Dose Levels)

Arm1 : This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly

DRUG

Placebo Drug

Arm2:placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).

Locations (1)

Peking University People's Hospital

Beijing, China